Soligenix (SNGX) EBT Margin (2010 - 2024)
Soligenix's (SNGX) quarterly EBT Margin came in at 70217.85% in Q2 2024, down 6943883.0% YoY from N/an in Q3 2023, and down 4190.4% on a QoQ basis from 1636.63% in Q1 2024.
Soligenix (SNGX) EBT Margin (2010 - 2024) Analysis & Trends
Soligenix (SNGX) has 15 years of EBT Margin data on file, last reported at 70217.85% in Q2 2024.
- Quarterly EBT Margin fell 6943883.0% year-over-year to 70217.85% in Q2 2024, while the trailing twelve-month figure through Dec 2024 was 7267.84% (down 632563.0% YoY) and the FY2024 annual result came in at 7267.84%, down 632563.0% from the prior year.
- EBT Margin retreated to 70217.85% in Q2 2024, from 1636.63% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 294.04% in Q3 2020 to a low of 70217.85% in Q2 2024.
- A 5-year average of 5093.62% and a median of 1280.15% in 2021 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin surged 145425 bps — and 2024, when it plunged 6943883 bps.
- Tracing SNGX's EBT Margin over 5 years: stood at 775.26% in 2020, then tumbled by 120 bps to 1706.45% in 2021, then jumped by 40 bps to 1025.37% in 2022, then advanced by 3 bps to 991.17% in 2023, then slumped by 6984 bps to 70217.85% in 2024.
- The last three EBT Margin figures came in at 70217.85% (Q2 2024), 1636.63% (Q1 2024), and 991.17% (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 12.09% |
| 10 | Soligenix | 6.09 Mn | 6.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -70,217.85% |
| Mar 31, 2024 | -1,636.63% |
| Dec 31, 2023 | -991.17% |
| Sep 30, 2023 | -1,274.69% |
| Jun 30, 2023 | -779.02% |
| Mar 31, 2023 | -858.28% |
| Dec 31, 2022 | -1,025.37% |
| Sep 30, 2022 | -1,991.70% |
| Jun 30, 2022 | -1,549.03% |
| Mar 31, 2022 | -2,312.53% |
| Dec 31, 2021 | -1,706.45% |
| Sep 30, 2021 | -1,926.74% |
| Jun 30, 2021 | -1,285.62% |
| Mar 31, 2021 | -1,600.67% |
| Dec 31, 2020 | -775.26% |
| Sep 30, 2020 | -294.04% |
| Jun 30, 2020 | -549.54% |
| Mar 31, 2020 | -910.52% |
| Dec 31, 2019 | -144.85% |
| Sep 30, 2019 | -287.31% |